Presentation is loading. Please wait.

Presentation is loading. Please wait.

Mitochondria-associated membranes in proximal tubules after ischemia.

Published byLanny Iskandar Modified over 5 years ago

Similar presentations

Presentation on theme: "Mitochondria-associated membranes in proximal tubules after ischemia."— Presentation transcript:

1 Mitochondria-associated membranes in proximal tubules after ischemia.
Mitochondria-associated membranes in proximal tubules after ischemia. Rats were treated with SS-31 (2 mg/kg per day) or saline for 1.5 months starting 1 month after acute ischemia. Proximal tubules were examined by transmission electron microscopy 9 months after ischemia. (A–D) Representative images showing membrane vesicles in close apposition to the OMM. (E and F) Representative images from SS-31-treated samples did not show these mitochondria-associated membranes. Hazel H. Szeto et al. JASN 2017;28: ©2017 by American Society of Nephrology

Download ppt "Mitochondria-associated membranes in proximal tubules after ischemia."

Similar presentations

Fast Fourier transform of atomic resolution high-resolution transmission electron microscopy images of a polycrystalline area from a lysed cell deposit.

Fast Fourier transform of atomic resolution high-resolution transmission electron microscopy images of a polycrystalline area from a lysed cell deposit.
Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.

Pioglitazone treatment prevents TRPC6 overexpression and podocyte injury in the adriamycin (ADRIA)–induced nephropathy rat model for FSGS. ADRIA-induced.
PDE5A is expressed by podocytes.

PDE5A is expressed by podocytes.
Relationship between urinary TNF-α and RANTES excretion

Relationship between urinary TNF-α and RANTES excretion
Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.

Differential expression of select miRNAs was validated in a second cohort of patients. Differential expression of select miRNAs was validated in a second.
Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.

Inhibition of ILK activity does not affect normal kidney structure and nephrin/ILK interaction in vivo. Inhibition of ILK activity does not affect normal.
Antibody–mediated C5 inhibition in hepatocyte-Cfh−/− mice during accelerated serum NTN. (A) Hematuria, (B) serum urea, (C) red cell fragments, (D) glomerular.

Antibody–mediated C5 inhibition in hepatocyte-Cfh−/− mice during accelerated serum NTN. (A) Hematuria, (B) serum urea, (C) red cell fragments, (D) glomerular.
Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.

Two independent amino acid positions were identified after stepwise association analysis for amino acids in HLA-DRβ1, HLA-DQα1 and HLA-DQβ1 in the combined.
Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.

Figure 1. Relationship between (A) total antioxidative activity (TAA) and endothelium-dependent vasodilation (EDV) (r = 0.41, P = 0.016), (B) lag phase.
Missense mutations in TNXB as a cause of VUR

Missense mutations in TNXB as a cause of VUR
Studies reporting the incident rate for ischemic steal syndrome per 1000 patient days. Studies reporting the incident rate for ischemic steal syndrome.

Studies reporting the incident rate for ischemic steal syndrome per 1000 patient days. Studies reporting the incident rate for ischemic steal syndrome.
Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.

Figure 3. Severity of aortic atherosclerosis in apo-E −/− mice with CRF. Aortic plaque area fraction (A), aortic cholesterol content (B), and aortic root.
Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF

Figure 2. Plasma lipoprotein cholesterol in apo-E −/− mice with CRF
Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.

Figure 1. Plasma urea concentrations in apolipoprotein E–deficient (apo-E −/−) mice with chronic renal failure (CRF). Figure 1. Plasma urea concentrations.
Na,K-ATPase displays distinct polarized localization in different tissues and developmental stages. Na,K-ATPase displays distinct polarized localization.

Na,K-ATPase displays distinct polarized localization in different tissues and developmental stages. Na,K-ATPase displays distinct polarized localization.
Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.
T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.
Studies reporting the incident rate for all types of infections per 1000 patient days. Studies reporting the incident rate for all types of infections.

Studies reporting the incident rate for all types of infections per 1000 patient days. Studies reporting the incident rate for all types of infections.
Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.

Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration. Figure 10. Recovery of the acetyl-CoA and ATP levels by glucose administration.
Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.

Several microRNAs are differentially expressed in the glomeruli between different types of kidney disease. Several microRNAs are differentially expressed.

Similar presentations

Ads by Google